NAR cancer

01 30 September 2026

DOI 10.1093/narcan/zcag027

N 6-methyladenosine promotes temozolomide resistance through mRNA stabilization in glioblastoma cells

Open DOI

Emily A Dangelmaier, Dorthy Fang, Isabel P Hardy et al.

N 6-methyladenosine (m6A) regulates nearly every aspect of messenger RNA (mRNA) processing and function, impacting downstream gene expression programs. Changes in m6A have been implicated in many different types of cancer, and inhibition...

Read abstract

02 27 July 2026

DOI 10.1093/narcan/zcag026

Integrative multi-omics profiling and machine learning reveal enhancer RNA signatures for early detection and prognostic stratification in breast cancer

Open DOI

Junhuan Xia, Jingwen Tian, Yuting Cao et al.

Current breast cancer biomarkers rely predominantly on protein-coding transcriptomes, leaving the regulatory information encoded by enhancer RNAs (eRNAs) largely unexploited. Here, we profiled eRNA expression across 1073 The Cancer Genom...

Read abstract

03 27 July 2026

DOI 10.1093/narcan/zcag025

IGF2BP3 remodels RISC occupancy to control microRNA targeting in leukemia

Open DOI

Lyna E S Kabbani, Shruti Kapoor, Gunjan Sharma et al.

IGF2BP3 is an oncofetal RNA-binding protein that promotes leukemogenesis, but the mechanisms by which it remodels post-transcriptional gene regulation remain incompletely understood. Because IGF2BP3 binds extensively within 3′ untranslat...

Read abstract

04 27 July 2026

DOI 10.1093/narcan/zcag020

LncRNA RAMS11 -dependent NOTCH3 activation drives tumor progression in non-small cell lung cancer

Open DOI

Gejae G Jeffers, Yesol Kim, Nicole M White et al.

Lung cancer is currently the leading cause of cancer-related deaths worldwide. Approximately 85% of lung cancer patients have non-small cell lung cancer (NSCLC), and >50% of these patients present with metastasis at their initial diagnos...

Read abstract

05 27 July 2026

DOI 10.1093/narcan/zcag024

Motif-centered analyses reveal universal and tissue-specific mutagenic mechanisms operating in the human body

Open DOI

Safia Mahabub Sauty, Yun-Chung Hsiao, Leszek J Klimczak et al.

Somatic mutations are inevitable in human genomes and can lead to cancer initiation and tumor progression. Although many mutagenic processes have been linked to cancer, their activities in normal tissues before malignant transformation r...

Read abstract

06 27 July 2026

DOI 10.1093/narcan/zcag023

STN1 upregulation promotes PARPi resistance in BRCA2-deficient cancer cells via replication fork protection and suppression of ssDNA gap formation

Open DOI

Zubair Ahmed Laghari, Na Li, Serdar Gayybov et al.

PARPi are effective therapy for BRCA1/2 mutant cancers, yet recurrent PARPi resistance frequently develops. The underlying mechanism of PARPi resistance remains largely unresolved. Here, we identify STN1, a component of the CTC1/STN1/TEN...

Read abstract

07 27 July 2026

DOI 10.1093/narcan/zcag022

In vivo selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft model

Open DOI

Caroline D Doherty, Sonia Jain, Lauren L Ott et al.

Glioblastoma (GBM) is an aggressive, high-grade glioma with a near-universally fatal prognosis. Therapeutic failure is often attributed to the highly selective blood-brain barrier (BBB), the diffuse infiltrative nature of the tumor, and ...

Read abstract

08 27 July 2026

DOI 10.1093/narcan/zcag021

Multi-omic cell free DNA profiles of cerebral spinal fluid from lung cancer metastasis to the brain

Open DOI

Tianqi Chen, Xiangqi Bai, Georgiana Burnside et al.

Cerebrospinal fluid (CSF) is a liquid biological medium immersing the brain and spinal canal. For patients with metastatic cancer from the lung, tumor cells release their cell-free DNA (cfDNA) into the CSF. We applied a nanopore single-m...

Read abstract

09 27 July 2026

DOI 10.1093/narcan/zcag019

SNHG family lncRNAs promote Ewing sarcoma cell fitness through intronic snoRNA-guided rRNA modifications

Open DOI

Marcela Briones-Martin-Del-Campo, Alex G Lee, Truc Dinh et al.

Over 90% of Ewing sarcomas (EWS) are driven by the EWS–FLI1 fusion oncoprotein. EWS–FLI1 acts as a pioneer transcription factor, altering the expression of hundreds of genes including many long non-coding RNAs (lncRNAs). The role of thes...

Read abstract

10 27 July 2026

DOI 10.1093/narcan/zcag017

A complex mutational signature generated by cytarabine resistance

Open DOI

Dengchao Cao, Mianmian Yin, Ryan Bertoli et al.

T-cell acute lymphoblastic leukemia (T-ALL) patients generally respond well to chemotherapy, but T-ALL cells at relapse are typically resistant to chemotherapy. The specific mechanisms leading to chemoresistance are incompletely understo...

Read abstract